logo

For the Inventor, By the Inventor

Kanagawa, Japan

Oncotherapy Science, Incorporated


USPTO Granted Patents = 150

% Expired Patents = 42.0



Forward Citations = 356

Loading Chart...
Loading Chart...

84 inventors (with patents filed for the assignee):

goldMedal Takuya Tsunoda (73 out of 73 patents)

silverMedal Yusuke Nakamura (54 out of 116 patents)

bronzeMedal Yusuke Nakamura (34 out of 65 patents)

4.  Shuichi Nakatsuru (33 out of 33 patents)

5.  Sachiko Yoshimura (32 out of 32 patents)

6.  Tomohisa Watanabe (30 out of 30 patents)

7.  Ryuji Ohsawa (28 out of 28 patents)

8.  Ryuji Osawa (27 out of 27 patents)

9.  Toyomasa Katagiri (23 out of 23 patents)

10.  Yasuharu Nishimura (19 out of 22 patents)

11.  Yoichi Furukawa (17 out of 19 patents)

12.  Hideaki Tahara (14 out of 17 patents)

13.  Yataro Daigo (11 out of 11 patents)

14.  Sachiko Yamashita (10 out of 10 patents)

15.  Tetsuro Hikichi (10 out of 10 patents)


Core Competencies:
Peptide Vaccines
Monoclonal Antibodies
Tumor-Targeting Agents
Cancer Treatment
Immune Response
Breast Cancer
FZD10 Antibodies
DEPDC1 Polypeptides
MELK Inhibitors
Th1 Cells
SPARC Peptides
Synovial Sarcoma

150 patents:

1. 12747265 - FOXM1-DERIVED PEPTIDE, AND VACCINE INCLUDING SAME (2026-09-29),
2. 12595289 - THERAPEUTIC AGENT FOR BREAST CANCER COMPRISING BIG3-PHB2 INTERACTION-INHIBITING PEPTIDE DERIVED FROM PHB2 (2026-04-07),
3. 12195559 - CDCA1-derived peptide and vaccine containing same (2025-01-14),
4. 11673915 - DEPDC1-derived peptide and vaccine containing same (2023-06-13),
5. 11598780 - Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor (2023-03-07),
6. 11547723 - KOC1-derived peptide and vaccine including same (2023-01-10),
7. 11266729 - UBE2T peptides and vaccines containing the same (2022-03-08),
8. 11242365 - FOXM1-derived peptide, and vaccine including same (2022-02-08),
9. 11091517 - Peptide derivative and pharmaceutical composition containing same (2021-08-17),
10. 11079386 - Monoclonal antibody against FZD10 and use thereof (2021-08-03),
11. 11066477 - Monoclonal antibody against MELK and utilization thereof (2021-07-20),
12. 10793599 - MPHOSPH1-derived peptide, and vaccine including same (2020-10-06),
13. 10711047 - CDCA1 epitope peptides and vaccines containing the same (2020-07-14),
14. 10676514 - CDCA1-derived peptide and vaccine containing same (2020-06-09),
15. 10676508 - DEPDC1-derived peptide and vaccine containing same (2020-06-09),
Company Overview
Oncotherapy Science, Incorporated, based in Kanagawa, Japan, specializes in the development of innovative cancer immunotherapy solutions. The company focuses on advanced therapeutic modalities, including peptide vaccines and monoclonal antibodies, aimed at enhancing the immune response against various cancers. Key areas of research include tumor-targeting agents and specific applications in breast cancer treatment, utilizing technologies such as FZD10 antibodies and DEPDC1 polypeptides to improve patient outcomes and advance cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Oncotherapy Science, Incorporated
150 Patents

#26 in Kanagawa

#856 in Japan

#5,436 in the World

Kanagawa, JP
Kanagawa, Japan

Oncotherapy Science, Incorporated

Forward Citations = 356

84 inventors:

goldMedal Takuya Tsunoda (73 out of 73 patents)

silverMedal Yusuke Nakamura (54 out of 116 patents)

bronzeMedal Yusuke Nakamura (34 out of 65 patents)

4.  Shuichi Nakatsuru (33 out of 33 patents)

5.  Sachiko Yoshimura (32 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncotherapy Science, Incorporated. Retrieved from https://idiyas.com/company/oncotherapy-science

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Please report any incorrect information to [email protected]
Loading…